MacroGenics (MGNX)
(Delayed Data from NSDQ)
$3.58 USD
-0.25 (-6.53%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $3.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
MacroGenics (MGNX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.78 | $13.00 | $4.00 | 103.13% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for MacroGenics comes to $7.78. The forecasts range from a low of $4.00 to a high of $13.00. The average price target represents an increase of 103.13% from the last closing price of $3.83.
Analyst Price Targets (9 )
Broker Rating
MacroGenics currently has an average brokerage recommendation (ABR) of 2.27 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.73 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, four are Strong Buy, representing 36.36% of all recommendations. A month ago, Strong Buy represented 63.64%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 7 | 7 | 7 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 7 | 4 | 4 | 4 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.27 | 1.73 | 1.73 | 1.73 | 1.36 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/1/2024 | BTIG | Kaveri Pohlman | Strong Buy | Hold |
8/1/2024 | H.C. Wainwright & Co. | Robert Burns | Hold | Hold |
7/31/2024 | Guggenheim Securities | Michael Schmidt | Strong Buy | Hold |
7/31/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
7/31/2024 | B. Riley Securities | Mayank Mamtani | Hold | Hold |
7/30/2024 | SVB Securities | Jonathan W Chang | Strong Buy | Strong Buy |
7/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/10/2024 | Cowen & Co. | Tara Bancroft | Strong Buy | Hold |
5/10/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Hold |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Hold |
12/20/2023 | Not Identified | Not Identified | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.27 |
ABR (Last week) | 1.73 |
# of Recs in ABR | 11 |
Average Target Price | $7.78 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 101 of 253 |
Current Quarter EPS Est: | -0.47 |